PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2007 |
| End Date: | March 2012 |
A Phase 1b Study to Assess the Safety, Feasibility, Pharmacokinetics, and Activity of PTC299 Monotherapy or Combination Therapy With Hormonal Agents in Patients With Metastatic Breast Cancer
Formation of new blood vessels (angiogenesis) is important for tumor growth in metastatic
breast cancer. It is known that tumors make a protein called vascular endothelial growth
factor (VEGF) and there are higher levels of VEGF in the tumors and blood of many women with
metastatic breast cancer. VEGF stimulates the formation of blood vessels that supply the
tumor with nutrients and oxygen. PTC299 is an oral drug that has been shown to decrease
production of VEGF in animal models of human cancer. In these animal models, oral PTC299
administration decreases VEGF levels in the tumor and in the bloodstream, decreases blood
vessel numbers in the tumor, and significantly slows or halts tumor growth. Safety studies
in research animals indicate good tolerability at doses and drug levels that are higher than
those planned for the clinical studies. Results from Phase 1a studies in healthy volunteers
indicate that PTC299 achieves levels of PTC299 in the bloodstream that are known to be
active in animal models of human cancer. This Phase 1b study is designed to test the
hypothesis that PTC299 will be tolerable and will show evidence of VEGF reduction and
antitumor activity when administered orally in combination with anastrozole (Arimidex®),
letrozole (Femara®), or exemestane (Aromasin®) to women with metastatic breast cancer.
breast cancer. It is known that tumors make a protein called vascular endothelial growth
factor (VEGF) and there are higher levels of VEGF in the tumors and blood of many women with
metastatic breast cancer. VEGF stimulates the formation of blood vessels that supply the
tumor with nutrients and oxygen. PTC299 is an oral drug that has been shown to decrease
production of VEGF in animal models of human cancer. In these animal models, oral PTC299
administration decreases VEGF levels in the tumor and in the bloodstream, decreases blood
vessel numbers in the tumor, and significantly slows or halts tumor growth. Safety studies
in research animals indicate good tolerability at doses and drug levels that are higher than
those planned for the clinical studies. Results from Phase 1a studies in healthy volunteers
indicate that PTC299 achieves levels of PTC299 in the bloodstream that are known to be
active in animal models of human cancer. This Phase 1b study is designed to test the
hypothesis that PTC299 will be tolerable and will show evidence of VEGF reduction and
antitumor activity when administered orally in combination with anastrozole (Arimidex®),
letrozole (Femara®), or exemestane (Aromasin®) to women with metastatic breast cancer.
The study will be conducted in 2 stages. In Stage 1 of the study, successive groups of 3 to
6 patients will receive progressively higher PTC299 dose levels; in this stage, treatment
will be given in repeated 6-week cycles consisting of 4 weeks of oral PTC299 twice per day
followed by a 2-week, no-drug period. During Stage 2, study candidates must be women with
natural or induced suppression of ovarian function to post-menopausal levels who are
receiving or are candidates for hormonal therapy. These subjects will receive continuous
administration of PTC299, 100 mg/dose BID, in repeated 6-week cycles in combination with
continuous administration of one of 3 hormonal agents. All planned PTC299 dose levels in all
stages are expected to achieve circulating blood levels of PTC299 known to be active in
animal models of human cancer. Treatment for each patient can continue as long as the
therapy appears to be safely offering tumor control to that patient. Up to 36 evaluable
patients will be accrued across both stages.
6 patients will receive progressively higher PTC299 dose levels; in this stage, treatment
will be given in repeated 6-week cycles consisting of 4 weeks of oral PTC299 twice per day
followed by a 2-week, no-drug period. During Stage 2, study candidates must be women with
natural or induced suppression of ovarian function to post-menopausal levels who are
receiving or are candidates for hormonal therapy. These subjects will receive continuous
administration of PTC299, 100 mg/dose BID, in repeated 6-week cycles in combination with
continuous administration of one of 3 hormonal agents. All planned PTC299 dose levels in all
stages are expected to achieve circulating blood levels of PTC299 known to be active in
animal models of human cancer. Treatment for each patient can continue as long as the
therapy appears to be safely offering tumor control to that patient. Up to 36 evaluable
patients will be accrued across both stages.
Major Eligibility Criteria:
1. Female sex.
2. Age ≥18 years.
3. Body weight 40-100 kg.
4. ECOG performance status of 0 or 1.
5. Histologically or cytologically confirmed adenocarcinoma of the breast.
6. Presence of metastatic disease not amenable to surgery, radiation therapy, or
chemoradiotherapy with curative intent.
7. No active second metastatic malignancy other than breast cancer.
8. No unstable brain or leptomeningeal disease.
9. Discontinuation of other therapies (except for anastrozole, letrozole, or exemestane)
for the treatment of breast cancer and resolution of any acute toxic effects of prior
therapies.
10. Adequate bone marrow, liver, and kidney function.
11. No uncontrolled hypertension, major bleeding, HIV infection or recent acute
cardiovascular event.
12. If sexually active and not postmenopausal or surgically sterile, willingness to
abstain from sexual intercourse or employ an effective barrier method of
contraception during the study drug administration and follow-up periods.
13. No pregnancy or breast-feeding.
14. Willingness and ability to comply with scheduled visits, drug administration plan,
laboratory tests, other study procedures, and study restrictions.
15. Willingness to provide informed consent. In addition to the criteria noted above,
Stage 2 subjects must also have natural or induced suppression of ovarian function to
post-menopausal levels and be receiving or be a candidate for hormonal therapy.
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials